| 查看: 746 | 回复: 3 | |||
[交流]
西替利嗪在儿童用药的主要风险是什么?
|
|
西替利嗪用于儿童,不同资料说法不一:包括“不推荐用于6岁以下儿童”,“不推荐用于12岁以下儿童”,“2岁以下儿童禁用”,“可用于儿童及妊娠或哺乳的妇女”不一而足。 目前权威的说法是? 西替利嗪在儿童用药的主要风险是什么? 希望有最新资料的站友给予解释 |
» 猜你喜欢
烦躁
已经有6人回复
» 本主题相关价值贴推荐,对您同样有帮助:
转:用创新承载梦想--扬子江药业致力新品名品开发研制巡礼
已经有15人回复
【转帖】强生制药双阴影:召回局未了,质量门添忧
已经有0人回复
» 抢金币啦!回帖就可以得到:
欢迎来稿
+5/800
求助DL 5009.1-2014
规程 第1部分:火力发电》
+1/490
同济大学化学系(有机化学、元素化学)2027级博士生招生
+1/297
南京理工大学国家级青年人才2027年博士招生(多智能体系统、多机器人系统方向)
+1/97
南开大学环境科学与工程学院 环境与人体健康方向 招博士研究生
+1/90
中南大学刘敏教授课题组招收博士后和教师
+1/87
军科结构生物学团队申请-考核制博士招生
+1/40
【2027硕士招生】招收材料、化工、环境、冶金类硕士研究生
+1/19
西安:诚征女友
+1/18
湖南大学-分析检测技术和生物柔性传感器-招收1名博士研究生 (2027年)
+1/18
招聘电池方向博士
+1/11
招聘电池方向博士
+1/8
双一流天津工业大学电信学院李鸿强教授招收2027年申请审核制博士3名
+1/6
中科院兰州化物所工业催化组招收2027年申请-考核制博士生
+1/5
PLA邻位连接技术:空间蛋白互作的精准定位与直观可视
+1/4
边缘计算与物联网大数据分析:联邦学习、流计算与TinyML边缘AI大模型本地部署与算力
+1/4
武汉大学电信学院-梁国镇课题组-诚招硕士博士 - 深紫外光源方向 - 2027年入学
+1/2
香港城市大学孙红燕课题组招收有化学生物学背景的研究助理,博士生和博士后
+1/1
哈尔滨工程大学动力学院赵建辉团队招收2027级博士研究生
+1/1
Ph.D. Student Positions in 6G and Open/AI RAN at Birthplace of Computer
+1/1
2楼2011-07-13 14:49:57
3楼2011-07-13 21:28:14
★
qinhy(金币+1): 谢谢回帖交流~ 2011-07-14 17:55:39
qinhy(金币+1): 谢谢回帖交流~ 2011-07-14 17:55:39
|
以下是国外网站的资料,显示对6个月以上儿童进行过安全性评价,应该可以使用。 国外上市的有片剂、糖浆剂和咀嚼片。 ZYRTEC (cetirizine) can be taken without regard to food consumption. ZYRTEC (cetirizine) is available as 5 mg and 10 mg tablets, 1 mg/mL syrup, and 5 mg and 10 mg chewable tablets which can be taken with or without water. Adults and Children 12 Years and Older: The recommended initial dose of ZYRTEC (cetirizine) is 5 mg or 10 mg per day in adults and children 12 years and older, depending on symptom severity. Most patients in clinical trials started at 10 mg. ZYRTEC (cetirizine) is given as a single daily dose. The time of administration may be varied to suit individual patient needs. Children 6 to 11 Years: The recommended initial dose of ZYRTEC (cetirizine) in children aged 6 to 11 years is 5 mg or 10 mg once daily depending on symptom severity. The time of administration may be varied to suit individual patient needs. Children 2 to 5 Years: The recommended initial dose of ZYRTEC (cetirizine) in children aged 2 to 5 years is 2.5 mg (? teaspoon) syrup once daily. The dosage in this age group can be increased to a maximum dose of 5 mg per day given as 1 teaspoon syrup once a day or one ? teaspoon syrup given every 12 hours, or one 5 mg chewable tablet once a day. Children 6 months to <2 years: The recommended dose of ZYRTEC (cetirizine) syrup in children 6 months to 23 months of age is 2.5 mg (? teaspoon) once daily. The dose in children 12 to 23 months of age can be increased to a maximum dose of 5 mg per day, given as ? teaspoon (2.5 mg) every 12 hours. Syrup is recommended for children under the age of 2 years. Pediatric Use: The safety of ZYRTEC (cetirizine) has been demonstrated in pediatric patients aged 6 months to 11 years. The safety of ZYRTEC (cetirizine) , at daily doses of 5 or 10 mg, has been demonstrated in 376 pediatric patients aged 6 to 11 years in placebo-controlled trials lasting up to four weeks and in 254 patients in a non-placebo-controlled 12-week trial. The safety of cetirizine has been demonstrated in 168 patients aged 2 to 5 years in placebo-controlled trials of up to 4 weeks duration. On a mg/kg basis, most of the 168 patients received between 0.2 and 0.4 mg/kg of cetirizine HCl. The safety of cetirizine in 399 patients aged 12 to 24 months has been demonstrated in a placebo-controlled 18-month trial, in which the average dose was 0.25 mg/kg bid, corresponding to a range of 4 to 11 mg/day. The safety of ZYRTEC (cetirizine) syrup has been demonstrated in 42 patients aged 6 to 11 months in a placebo-controlled 7-day trial. The prescribed dose was 0.25 mg/kg bid, which corresponded to a mean of 4.5 mg/day, with a range of 3.4 to 6.2 mg/day. The effectiveness of ZYRTEC (cetirizine) for the treatment of allergic rhinitis and chronic idiopathic urticaria in pediatric patients aged 6 months to 11 years is based on an extrapolation of the demonstrated efficacy of ZYRTEC (cetirizine) in adults with these conditions and the likelihood that the disease course, pathophysiology and the drug's effect are substantially similar between these two populations. Efficacy is extrapolated down to 6 months of age for perennial allergic rhinitis and down to 2 years of age for seasonal allergic rhinitis because these diseases are thought to occur down to these ages in children. The recommended doses for the pediatric population are based on cross-study comparisons of the pharmacokinetics and pharmacodynamics of cetirizine in adult and pediatric subjects and on the safety profile of cetirizine in both adult and pediatric patients at doses equal to or higher than the recommended doses. The cetirizine AUC and Cmax in pediatric subjects aged 6 to 23 months who received a mean of 2.3 mg in a single dose, and in subjects aged 2 to 5 years who received a single dose of 5 mg of cetirizine syrup and in pediatric subjects aged 6 to 11 years who received a single dose of 10 mg of cetirizine syrup were estimated to be intermediate between that observed in adults who received a single dose of 10 mg of cetirizine tablets and those who received a single dose of 20 mg of cetirizine tablets. The safety and effectiveness of cetirizine in pediatric patients under the age of 6 months have not been established. Last reviewed on RxList: 5/17/2007 This monograph has been modified to include the generic and brand name in many instances. 别人的回复,贴到这,与同道共享 |
4楼2011-07-14 10:35:31










回复此楼